Abstract
Stricter bioequivalence criteria are in place for generics where there are narrow therapeutic indexes such as generic immunosuppressives, enhancing their acceptance despite limited published studies. No serious issues have been reported to date with generic ciclosporin despite being on the market in Europe for more than 10 years.
Original language | English |
---|---|
Pages (from-to) | 159-160 |
Number of pages | 2 |
Journal | GaBI Journal |
Volume | 4 |
Issue number | 4 |
DOIs |
|
Publication status | Published - 2015 |
Externally published | Yes |
Keywords
- Bioequivalence
- Ciclosporin
- EMA
- Generics
- Immunosuoppressives
- Narrow therapeutic index drugs